PriceTargets.com logo

Exicure - XCUR Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.51 As of 04/25/2024 06:13 PM ET
▼ -0.006 (-1.17%)

This chart shows the closing price for XCUR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Exicure Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for XCUR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for XCUR

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Exicure in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.51.

This chart shows the closing price for XCUR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Exicure. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/13/2021Chardan CapitalDowngradeBuy ➝ NeutralHigh
11/23/2021Chardan CapitalLower TargetBuy$210.00 ➝ $67.50Low
8/31/2021HC WainwrightReiterated RatingBuy$180.00Low
5/17/2021HC WainwrightLower TargetBuy$240.00 ➝ $180.00High
3/4/2021HC WainwrightReiterated RatingBuyHigh
12/18/2020BMO Capital MarketsInitiated CoverageOutperform$180.00High
12/9/2020HC WainwrightReiterated RatingBuyHigh
9/17/2020Chardan CapitalBoost TargetBuy$150.00 ➝ $210.00High
6/16/2020HC WainwrightReiterated RatingBuy$240.00Medium
6/4/2020GuggenheimReiterated RatingBuy$270.00Medium
6/4/2020LADENBURG THALM/SH SHReiterated RatingBuy$540.00Medium
5/15/2020HC WainwrightReiterated RatingBuy$240.00Medium
4/2/2020Chardan CapitalReiterated RatingBuy$150.00High
3/4/2020HC WainwrightReiterated RatingBuy$240.00High
3/4/2020Chardan CapitalReiterated RatingBuy$150.00High
12/24/2019HC WainwrightReiterated RatingBuy$240.00Medium
12/11/2019HC WainwrightReiterated RatingBuy$240.00High
11/27/2019GuggenheimInitiated CoverageBuy$270.00High
11/21/2019HC WainwrightReiterated RatingBuy$240.00Low
11/20/2019GuggenheimInitiated CoverageBuy$270.00Medium
11/6/2019HC WainwrightReiterated RatingBuyHigh
11/6/2019HC WainwrightInitiated CoverageBuyHigh
(Data available from 4/25/2019 forward)

News Sentiment Rating

0.07 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Exicure logo
Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Read More

Today's Range

Now: $0.51
Low: $0.51
High: $0.52

50 Day Range

MA: $0.62
Low: $0.52
High: $0.74

52 Week Range

Now: $0.51
Low: $0.36
High: $1.50

Volume

18,687 shs

Average Volume

382,557 shs

Market Capitalization

$4.40 million

P/E Ratio

0.30

Dividend Yield

N/A

Beta

1.31

Frequently Asked Questions

What sell-side analysts currently cover shares of Exicure?

The following Wall Street sell-side analysts have issued research reports on Exicure in the last year:
View the latest analyst ratings for XCUR.

What is the current price target for Exicure?

0 Wall Street analysts have set twelve-month price targets for Exicure in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Exicure in the next year.
View the latest price targets for XCUR.

What is the current consensus analyst rating for Exicure?

Exicure currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for XCUR.

What other companies compete with Exicure?

Other companies that are similar to Exicure include Petros Pharmaceuticals, NexImmune, Processa Pharmaceuticals, Longeveron and China Pharma. Learn More about companies similar to Exicure.

How do I contact Exicure's investor relations team?

Exicure's physical mailing address is 2430 N. Halsted St., Chicago IL, 60614. The company's listed phone number is (847) 673-1700 and its investor relations email address is [email protected]. The official website for Exicure is www.exicuretx.com. Learn More about contacing Exicure investor relations.